Search research articles
Contact Us
Filters
Showing results (81-90 of 114) with videos related to
Page
of 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
F Barlesi, A Scherpereel, V Gorbunova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
E-H Tan, R Ramlau, A Pluzanska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
E F Smit, M A Socinski, B P Mullaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
A S Mansfield, A Każarnowicz, N Karaseva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
D E Gerber, L Horn, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2021
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>
D R Spigel, D Vicente, T E Ciuleanu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Cell Reports
|
January 12, 2025
A conserved switch to less catalytically active Polycomb repressive complexes in non-dividing cells
Rachel McCole, James Nolan, David M Reck, et al.
ESMO Open
|
November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
H Borghaei, K J O'Byrne, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
H Borghaei, F de Marinis, D Dumoulin, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 114) with videos related to
Sort By:
Page
of 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
F Barlesi, A Scherpereel, V Gorbunova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
E-H Tan, R Ramlau, A Pluzanska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
E F Smit, M A Socinski, B P Mullaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
A S Mansfield, A Każarnowicz, N Karaseva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
D E Gerber, L Horn, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2021
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>
D R Spigel, D Vicente, T E Ciuleanu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Cell Reports
|
January 12, 2025
A conserved switch to less catalytically active Polycomb repressive complexes in non-dividing cells
Rachel McCole, James Nolan, David M Reck, et al.
ESMO Open
|
November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
H Borghaei, K J O'Byrne, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
H Borghaei, F de Marinis, D Dumoulin, et al.
Page
of 12